|
|
Article: Alkermes announces results of first Phase I clinical trial of ProLease human growth hormone.
- Article from:
- Business Wire
- Article date:
- November 14, 1996
CopyrightCOPYRIGHT 1996 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 1996--
One injection provides sustained Growth Hormone levels for three
to four weeks in adult patients
Alkermes, Inc. (NASDAQ: ALKS) today announced the results of a U.S. Phase I clinical trial of ProLease human growth hormone. The results, presented at the Second International Meeting of the Growth Hormone Research Society in London, England, showed that a single injection of ProLease human growth hormone resulted in elevated levels of human growth hormone (hGH), its key growth promoting protein, insulin like growth factor-I (IGF-I), and IGF-I's binding protein IGFBP-3, for three to four ...